Imipramine treatment reverses depressive-like behavior in alloxan-diabetic rats

Diabetes/Metabolism Research and Reviews

Volumn 28, Issue 2, 2012, Pages 139-144

  Ceretta, Luciane B ^a   Réus, Gislaine Z ^a   Stringari, Roberto B ^a   Ribeiro, Karine F ^a   Zappellini, Giovanni ^a   Aguiar, Bianca W ^b   Pfaffenseller, Bianca ^b   Lersh, Camila ^b   Kapczinski, Flávio ^b   Quevedo, João ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

BDNF; Depression; Diabetes; Forced swimming test; Imipramine

Indexed keywords

ALLOXAN; BRAIN DERIVED NEUROTROPHIC FACTOR; IMIPRAMINE; SODIUM CHLORIDE;

ALLOXAN DIABETES MELLITUS; AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; FORCED SWIMMING TEST; HIPPOCAMPUS; IMMOBILIZATION; MALE; NONHUMAN; OPEN FIELD TEST; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; REARING;

ALLOXAN; AMYGDALA; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSIVE DISORDER; DIABETES MELLITUS, EXPERIMENTAL; HIPPOCAMPUS; IMIPRAMINE; MALE; PREFRONTAL CORTEX; RATS; RATS, WISTAR;

EID: 84857022298     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1285     Document Type: Article

References (72)

1. Dismuke CE, Egede LE. Association between major depression, depressive symptoms and personal income in US adults with diabetes. Gen Hosp Psychiatry 2010; 32: 484-491.
2. Held RF, DePue J, Rosen R, et al. Patient and health care provider views of depressive symptoms and diabetes in American Samoa. Cultur Divers Ethnic Minor Psychol 2010; 16: 461-467.
3. Manderbacka K, Sund R, Koski S, Keskimäki I, Elovainio M. Diabetes and depression? Secular trends in the use of antidepressants among persons with diabetes in Finland in 1997-2007. Pharmacoepidemiol Drug Saf 2011; 20: 338-343.
4. Raval A, Dhanaraj E, Bhansali A, Grover S, Tiwari P. Prevalence & determinants of depression in type 2 diabetes patients in a tertiary care centre. Indian J Med Res 2010; 132: 195-200.
5. Egede LE, Simpson K. Epidemiology, treatment and costs of depression in adults with Type 2 diabetes. Expert Rev Pharmacoecon Outcomes Res 2003; 3: 251-262.
6. Pouwer F, Kupper N, Adriaanse MC. Does emotional stress cause type 2 diabetes mellitus? A review from the European Depression in Diabetes (EDID) Research Consortium. Discov Med 2010; 9: 112-118.
7. Knol M, Twisk J, Beekman A, Heine R, Snoek F, Pouwer F. Depression as a risk factor for the onset of type 2 diabetes: a meta-analysis. Diabetologia 2006; 49: 837-845.
8. Khazaie H, Rahimi M, Tatari F, Rezaei M, Najafi F, Tahmasian M. Treatment of depression in type 2 diabetes with Fluoxetine or Citalopram? Neurosciences 2011; 16: 42-45.
9. Franconi F, Seghieri G, Canu S, Straface E, Campesi I, Malorni W. Are the available experimental models of type 2 diabetes appropriate for a gender perspective? Pharmacol Res 2008; 57: 6-18.
10. Gomez R, Barros HMT. Ethopharmacology of the antidepressant effect of clonazepam in diabetic rats. Pharmacol Biochem Behav 2000; 66: 329-335.
11. Hilakivi-Clarke LA, Wozniak KM, Durcan MJ, Linnoila M. Behavior of streptozotocin-diabetic mice in tests of exploration, locomotion, anxiety, depression and aggression. Physiol Behav 1990; 48: 429-433.
12. Wayhs CAY, Manfredini V, Sitta A, et al. Effects of insulin and clonazepam on DNA damage in diabetic rats submitted to the forced swimming test. Mutat Res 2010; 703: 187-190.
13. Haeser AS, Sitta A, Barschak AG, et al. Oxidative stress parameters in diabetic rats submitted to forced swimming test: the clonazepam effect. Brain Res 2007; 1154: 137-143.
14. Réus GZ, Stringari RB, Ribeiro KF, et al. Ketamine plus imipramine treatment induces antidepressant-like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain. Behav Brain Res 2011; 221: 166-171.
15. Duman RS. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromol Med 2004; 5: 11-25.
16. Rao AA, Sridhar GR, Srinivas B, Das UN. Bioinformatics analysis of functional protein sequences reveals a role for brain-derived neurotrophic factor in obesity and type 2 diabetes mellitus. Med Hypotheses 2008; 70: 424-249.
17. Taliaz D, Loya A, Gersner R, Haramati S, Chen A, Zangen A. Resilience to chronic stress is mediated by hippocampal brain-derived neurotrophic factor. J Neurosci 2011; 31: 4475-4483.
18. Lindsay RM, Wiegand SJ, Altar CA, DiStefano PS. Neurotrophic factors: from molecule to man. Trends Neurosci 1994; 17: 182-190.
19. Castren E, Vooikar V, Rantamaki T. Role of neurotrophic factors in depression. Curr Opin Pharmacol 2007; 7: 18-21.
20. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59: 1116-1127.
21. Krabbe KS, Nielsen AR, Krogh-Madsen R, et al. Brain-derived neurotropic factor (BDNF) and type 2 diabetes. Diabetologia 2006; 50: 431-438.
22. Suwa M, Kishimoto H, Nofuji Y, et al. Serum brain-derived neurotrophic factor level is increased and associated with obesity in newly diagnosed female patients with type 2 diabetes mellitus. Metabolism 2006; 55: 852-857.
23. Kitamura Y, Araki H, Gomita Y. Influcence of ACTH on the effects of imipramine, desipramine and lithium on duration of immobility of rats in the forced swim test. Pharmacol Biochem Behav 2002; 71: 63-69.
24. Behr GA, da Silva EG, Ferreira AR, Cerskib CTS, Dal-Pizzol F, Moreira JCF. Pancreas b-cells morphology, liver antioxidant enzymes and liver oxidative parameters in alloxan-resistant and alloxan-susceptible Wistar rats: a viable model system for the study of concepts into reactive oxygen species. Fundam Clin Pharmacol 2008; 22: 657-666.
25. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 2001; 50: 536-546.
26. Detke MJ, Rickels M, Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacol 1995; 121: 66-72.
27. Garcia LB, Comim CM, Valvassori SS, et al. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 2008a; 32: 140-144.
28. Garcia LB, Comim CM, Valvassori SS, et al. Chronic administration of ketamine elicits antidepressant-like effects in rats without affecting hippocampal brain-derived neurotrophic factor protein levels. Basic Clinic Pharmacol Toxicol 2008b; 103: 502-506.
29. Porsolt RD, Le Pichon M, Jalfre M. Animal model of depression. Nature 1977; 266: 730-732.
30. Paxinos G, Watson C. The Rat Brain: Stereotaxic Coordinates (Second ed. edn). Academic Press: Australia, 1986.
31. Lowry OH, Rosebough NG, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
32. Robles GI, Singh-Franco D. A review of exenatide as adjunctive therapy in patients with type 2 diabetes. Drug Des Devel Ther 2009; 3: 219-240.
33. Bellush LL, Reid S, North D. The functional significance of biochemical alterations in streptozotocin-induced diabetes. Physiol Behav 1991; 50: 973-981.
34. Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
35. Arentoft A, Sweat V, Starr V, et al. Plasma BDNF is reduced among middle-aged and elderly women with impaired insulin function: evidence of a compensatory mechanism. Brain Cogn 2009; 71: 147-152.
36. Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: an overview. Indian J Med Res 2007; 125: 451-472.
37. Gruzman A, Elgart A, Viskind O, et al. Antihyperglycaemic activity of 2, 4:3, 5-dibenzylidene-D-xylose-dithioacetal in diabetic mice. J Cell Mol Med 2011, DOI: 10.1111/j.1582-4934.2011.01340.x.
38. Ceretta LB, Réus GZ, Rezin GT, Scaini G, Streck EL, Quevedo J. Brain energy metabolism parameters in an animal model of diabetes. Metab Brain Dis 2010; 25: 391-396.
39. Golden SH, Lazo M, Carnethon M, et al. Examining a bidirectional association between depressive symptoms and diabetes. JAMA 2008; 299: 2751-2759.
40. Shen C, Findley P, Banerjea R, Sambamoorthi U. Depressive disorders among cohorts of women veterans with diabetes, heart disease, and hypertension. J Womens Health (Larchmt) 2010; 19: 1475-1486.
41. Bot M, Pouwer F, Ormel J, Slaets JP, de Jonge P. Predictors of incident major depression in diabetic outpatients with subthreshold depression. Diabet Med 2010; 27: 1295-1301.
42. Ciechanowski PS, Katon WJ, Russo JE, Hirsh IB. The relationship of depressive symptoms to symptom reporting, self-care and glucose control in diabetes. Gen Hosp Psychiatry 2003; 25: 246-252.
43. Katon W, Von Korff M, Ciechanowski P, et al. Behavioral and clinical factors associated with depression among individuals with diabetes. Diabetes Care 2004a; 27: 914-920.
44. Katon WJ, Lin EH, Russo J, et al. Cardiac risk factors in patients with diabetes mellitus and major depression. J Gen Intern Med 2004b; 19: 1192-1199.
45. van der Feltz-Cornelis CM, Nuyen J, Stoop C, et al. Effect of interventions for major depressive disorder and significant depressive symptoms in patients with diabetes mellitus: a systematic review and meta-analysis. Gen Hosp Psychiatry 2010; 32: 380-395.
46. Pearce DA, Atkinson M, Tagle DA. Glutamic acid decarboxylase autoimmunity in Batten disease and other disorders. Neurology 2004; 63: 2001-2005.
47. Sharma AN, Elased KM, Garrett TL, Lucot JB. Neurobehavioral deficits in db/db diabetic mice. Physiol Behav 2010; 101: 381-388.
48. Hirano S, Miyata S, Kamei J. Antidepressant-like effect of leptin in streptozotocin-induced diabetic mice. Pharmacol Biochem Behav 2007; 86: 27-31.
49. Rajtar G, Zolkowska D, Keinrok Z. Effect of diazepam and clonazepam on the function of isolated rat platelet and neutrophils. Intern Med J Exp Clin Res 2002; 8: 37-44.
50. Massol J, Martin P, Belon JP, Puech AJ, Soubrié P. Helpless behavior (escape deficits) in streptozotocin-diabetic rats: resistance to antidepressant drugs. Psychoneuroendocrinology 1989; 14: 145-153.
51. Anjaneyulu M, Chopra K, Kaur I. Antidepressant activity of quercetin, a bioflavonoid, in streptozotocin-induced diabetic mice. J Med Food 2003; 6: 391-395.
52. Collin M, Hakansson-Ovesjo ML, Misane I, Ogren SO, Meister B. Decreased 5-HT transporter mRNA in neurons of the dorsal raphe nucleus and behavioral depression in the obese leptin-deficient ob/ob mouse. Brain Res Mol Brain Res 2000; 81: 51-61.
53. Crawley JN, Belknap JK, Collins A, et al. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology 1997; 132: 107-124.
54. den Heijer T, Vermeer SE, van Dijk EJ, et al. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 2003; 46: 1604-1610.
55. Yu H, Chen ZY. The role of BDNF in depression on the basis of its location in the neural circuitry. Acta Pharmacol Sin 2011; 32: 3-11.
56. Reichardt LF. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 2006; 361: 1545-1564.
57. Yoshii A, Constantine-Paton M. Postsynaptic BDNFTrkB signaling in synapse maturation, plasticity and disease. Dev Neurobiol 2010; 70: 304-322.
58. Akkermann K, Hiio K, Villa I, Harro J. Food restriction leads to binge eating dependent upon the effect of the brain-derived neurotrophic factor Val66Met polymorphism. Psych Res 2011; 185: 39-43.
59. Nonomura T, Tsuchida A, Ono-Kishino M, Nakagawa T, Taiji M, Noguchi H. Brain-derived neurotrophic factor regulates energy expenditure through the central nervous system in obese diabetic mice. Int J Exp Res 2001; 2: 201-209.
60. Ono M, Itakura Y, Nonomura T, et al. Intermittent administration of brain-derived neurotrophic factor ameliorates glucose metabolism in obese diabetic mice. Metabolism 2000; 49: 129-133.
61. Yeo GS, Connie Hung CC, Rochford J, et al. A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci 2004; 7: 1187-1189.
62. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psych Res 2002; 15: 143-148.
63. Kozisek ME, Middlemas D, Bylund DB. Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in themechanism of action of antidepressant therapies. Pharmacol Ther 2008; 117: 30-51.
64. De Foubert G, Carney SL, Robinson CS, et al. Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. Neuroscience 2004; 128: 597-604.
65. Tozuka Y, Kumona M, Wadaa E, Onoder M, Mochizuki H, Wada K. Maternal obesity impairs hippocampal BDNF production and spatial learning performance in young mouse offspring. Neuroch Inter 2010; 57: 235-247.
66. Yamanaka M, Itakura Y, Inoue T, et al. Protective effect of brain-derived neurotrophic factor on pancreatic islets in obese diabetic mice. Metabolism 2006; 55: 1286-1292.
67. Yamanaka M, Itakura Y, Ono-Kishino M, Tsuchida A, Nakagawa T, Taiji M. Intermittent administration of brain-derived neurotrophic factor (BDNF) ameliorates glucose metabolism and prevents pancreatic exhaustion in diabetic mice. J Biosci Bioeng 2008a; 105: 395-402.
68. Yamanaka M, Itakura Y, Tsuchida A, Nakagawa T, Taiji M. Brain-derived neurotrophic factor (BDNF) prevents the development of diabetes in prediabetic mice. Biomed Res 2008b; 29: 147-153.
69. Du F, Wang I, Qian W, Liu S. Loss of enteric neurons accompanied by decreased expression of GDNF and PI3K/Akt pathway in diabetic rats. Neurogastroenterol Motil 2009; 21: 1229.
70. Grünblatt E, Koutsilieri E, Hoyer S, Riederer P. Gene expression alterations in brain areas of intracerebroventricular streptozotocin treated rat. J Alzheimers Dis 2006; 9: 261-271.
71. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002; 34: 13-25.
72. Altar CA. Neurotrophins and depression. Trends Pharmacol Sci 1999; 20: 59-61.